Mega Lifesciences Financials
| MEGA Stock | THB 35.25 0.25 0.70% |
Mega |
Understanding current and past Mega Lifesciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Mega Lifesciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Mega Lifesciences' assets may result in an increase in income on the income statement.
Mega Lifesciences Stock Summary
Mega Lifesciences competes with AP Public, Advanced Information, AJ Plast, and Berli Jucker. Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures, markets, and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast moving consumer goods. Mega Lifesciences Public Company Limited is a subsidiary of Unistretch Limited. MEGA LIFESCIENCES operates under Drug Manufacturers - Major classification in Thailand and is traded on Stock Exchange of Thailand.| Foreign Associate | USA |
| Instrument | Thailand Stock View All |
| Exchange | Thailand Exchange |
| ISIN | TH4984010009 |
| Business Address | 909, Ample Tower, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.megawecare.com |
| Phone | 66 2 769 4222 |
| Currency | THB - Thailand Baht |
You should never invest in Mega Lifesciences without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Mega Stock, because this is throwing your money away. Analyzing the key information contained in Mega Lifesciences' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Mega Lifesciences Key Financial Ratios
Mega Lifesciences' financial ratios allow both analysts and investors to convert raw data from Mega Lifesciences' financial statements into concise, actionable information that can be used to evaluate the performance of Mega Lifesciences over time and compare it to other companies across industries.Mega Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mega Lifesciences's current stock value. Our valuation model uses many indicators to compare Mega Lifesciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mega Lifesciences competition to find correlations between indicators driving Mega Lifesciences's intrinsic value. More Info.Mega Lifesciences Public is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.43 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Mega Lifesciences Public is roughly 2.35 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mega Lifesciences' earnings, one of the primary drivers of an investment's value.Mega Lifesciences Public Systematic Risk
Mega Lifesciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Mega Lifesciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Mega Lifesciences Public correlated with the market. If Beta is less than 0 Mega Lifesciences generally moves in the opposite direction as compared to the market. If Mega Lifesciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Mega Lifesciences Public is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Mega Lifesciences is generally in the same direction as the market. If Beta > 1 Mega Lifesciences moves generally in the same direction as, but more than the movement of the benchmark.
Mega Lifesciences November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Mega Lifesciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Mega Lifesciences Public. We use our internally-developed statistical techniques to arrive at the intrinsic value of Mega Lifesciences Public based on widely used predictive technical indicators. In general, we focus on analyzing Mega Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Mega Lifesciences's daily price indicators and compare them against related drivers.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 11.46 | |||
| Value At Risk | (2.48) | |||
| Potential Upside | 3.16 |
Other Information on Investing in Mega Stock
Mega Lifesciences financial ratios help investors to determine whether Mega Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mega with respect to the benefits of owning Mega Lifesciences security.